Corentin Orvain

36PUBLICATIONS
149CO-AUTHORS
Haematological tumoursHaematologyRegenerative medicine (incl. stem cells)Predictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Sep 18, 2026
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.

|Sep 01, 2026
Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

|Mar 19, 2026
Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial.

Mathilde Taillantou-Candau, Achille Kouatchet, Astrid Darsonval

|Oct 08, 2025
Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.

Marie Sébert, Sylvain Thepot, Thomas Cluzeau

|Sep 08, 2025
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla

|Jul 29, 2025
Clusterin and pentraxin 3 are markers of severity during febrile neutropenia in adults with haematological malignancies receiving intensive chemotherapy.

Coralie Mallebranche, Carole Mosnier, Corentin Orvain

Pageof 6

Frequent Collaborators

9 joint publications

Damien Luque-Paz

8 joint publications

Sarah Bertoli

6 joint publications

Christian Récher

6 joint publications

Roland Walter